HBK Investments’s Envoy Medical COCH Stock Holding History

HBK Investments’s Portfolio COCH Stock Details COCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-764,759	Closed	-$7.5M	–	444
2022 Q2	$7.5M	Buy	764,759 +14,759	+2%	+$144K	0.04%	139
2022 Q1	$7.33M	Hold	750,000	–	–	0.03%	175
2021 Q4	$7.3M	Hold	750,000	–	–	0.03%	186
2021 Q3	$7.28M	Hold	750,000	–	–	0.03%	184
2021 Q2	$7.3M	Buy	+750,000	New	+$7.29M	0.03%	195

Other funds holding COCH

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

HBK Investments's COCH Position: Q3 2022 in Review

HBK Investments sold out of Envoy Medical (COCH) in Q3 2022, closing a stake of 764,759 shares — an estimated $7.5M sold.

HBK Investments first reported a position in COCH in Q2 2021 and held it in 5 quarters. The position peaked at $7.5M in Q2 2022. 94 funds tracked by Wall St. Rank hold COCH as of Q3 2022.

HBK Investments reported no remaining Envoy Medical position as of Q3 2022 after selling out during the quarter.
HBK Investments sold 764,759 Envoy Medical shares in Q3 2022, an estimated $7.5M.
HBK Investments first reported a position in Envoy Medical in Q2 2021 and held it in 5 quarters.
HBK Investments's Envoy Medical position peaked at $7.5M in Q2 2022.
94 funds tracked by Wall St. Rank held Envoy Medical as of Q3 2022.

Based on HBK Investments's 13F filing for Q3 2022, filed 14 Nov 2022.